Formycon

@formycon

Formycon is an independent developer of high-quality biosimilars with focus on treatments in ophthalmology, immunology and other key chronic diseases

Vrijeme pridruživanja: siječanj 2019.

Tweetovi

Blokirali ste korisnika/cu @formycon

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @formycon

  1. 3. velj

    offer an opportunity to help reduce total biologic drug spend. They could save between $54 to $250 bn over their first 10 years on the market. According to a recent estimate, there are more than 1000 biosimilars in any stage of the pipeline

    Poništi
  2. proslijedio/la je Tweet
    24. sij

    The market is expected to expand in the coming years as many reference drugs will soon lose patent exclusivity. By 2026, could save as much as $150 billion according to a recent article in . More:

    Poništi
  3. 21. sij

    The next decade of biologics facing loss of exclusivity will define the opportunities available to manufacturers.

    Poništi
  4. proslijedio/la je Tweet
    17. sij

    Biosimilar Uptake in Europe: Big Challenges; Bigger Rewards. Our colleague & Chair of the Biosimilar medicines group Isabell Remus outlines her vision for the future of medicines in (via PharmaBoardroom)

    Poništi
  5. 17. sij
    Poništi
  6. 16. sij

    Top product forecasts for 2020: Global Sales for and are estimated to be more than USD 7 billion each. An enormous target market for

    Poništi
  7. proslijedio/la je Tweet

    Great piece highlighting the FDA CDER team approving a record number of biosimilars in 2019, increasing choice for patients across the U.S. I’m looking forward to advancing biosimilars even further with and in 2020.

    Poništi
  8. proslijedio/la je Tweet
    7. sij

    Heute im : Dieses Jahr verlieren in Deutschland Medikamente mit einem Gesamtumsatz von knapp 700 Millionen Euro ihren Patentschutz - größtenteils Biopharmazeutika. haben ein riesiges Sparpotential fürs Gesundheitswesen!

    Poništi
  9. 20. pro 2019.
    Poništi
  10. 17. pro 2019.

    In Deutschland etablieren sich zu einer festen Größe im . Der durchschnittliche verfügbarer Biosimilars beträgt bereits 54,4%.

    Poništi
  11. 16. pro 2019.

    Von den Maßnahmen des bay. sollen auch profitieren. Der bay. spricht sich für Regularien für Generika und Biosimilars aus um das Potenzial für eine nachhaltige weiter auszuschöpfen.

    Poništi
  12. proslijedio/la je Tweet
    Poništi
  13. 2. pro 2019.

    Very interesting article about the coming age of . It is estimated that by 2025 biosimilars will reach a worldwide market value of over $61 Billion. The coming age of biosimilars | Pharmafile

    Poništi
  14. 29. stu 2019.

    A joint report has been issued by the European Commission (EC) and the UK Organisation for Economic Co-operation and Development (OECD) on in the EU, highlighting the importance of generics and for HealthCare Systems.

    Poništi
  15. 22. stu 2019.

    Formycon is looking forward to present financial figures and corporate developments to , and at on November 26 at

    Poništi
  16. 21. stu 2019.

    This is exactly what are supposed to do: Enabling broad to high and highly for the treatment of serious .

    Poništi
  17. 14. stu 2019.

    Formycon Reports Its Nine-Month Figures For 2019

    Poništi
  18. 13. stu 2019.

    Impressive Forecast: U.S. market is projected to reach around USD 17 Billion in 2026

    Poništi
  19. 8. stu 2019.

    appreciates that Bioeq IP AG, the exclusive owner of the global commercialization rights of , has signed a license and development agreement with Coherus BioSciences, Inc. to market and distribute 's ´ candidate to (FYB201) in the US

    Poništi
  20. 6. stu 2019.

    ist happy to announce that IP AG exclusively Marketing Rights for to Coherus BioSciences, Inc. We consider as a strong and competent for a successful of FYB201 in the US.

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·